Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to $4.6 million.

  • Therapeutics' Share-based Compensation rose 3.61% to $4.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $19.9 million, marking a year-over-year increase of 16.64%. This contributed to the annual value of $19.9 million for FY2024, which is 16.64% up from last year.
  • As of Q4 2024, Therapeutics' Share-based Compensation stood at $4.6 million, which was up 0.55% from $4.6 million recorded in Q3 2024.
  • In the past 5 years, Therapeutics' Share-based Compensation ranged from a high of $5.4 million in Q1 2024 and a low of $2.0 million during Q3 2020.
  • Its 3-year average for Share-based Compensation is $4.0 million, with a median of $4.3 million in 2023.
  • Per our database at Business Quant, Therapeutics' Share-based Compensation dropped by 18.45% in 2021 and then skyrocketed by 58.65% in 2023.
  • Over the past 5 years, Therapeutics' Share-based Compensation (Quarterly) stood at $2.6 million in 2020, then declined by 18.45% to $2.1 million in 2021, then soared by 45.01% to $3.0 million in 2022, then spiked by 46.41% to $4.4 million in 2023, then rose by 3.61% to $4.6 million in 2024.
  • Its Share-based Compensation stands at $4.6 million for Q4 2024, versus $4.6 million for Q3 2024 and $5.4 million for Q2 2024.